Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTX-109 for Nasal Decolonisation of S. aureus
NCT05889351Phase 2Completed
- Sponsor
- Pharma
- Start
- Sep 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of voxvoganan in Staphylococcus aureus carriage, sponsored by Pharma. Started Sep 2022; status: completed.
02
Drugs
voxvoganan
03
Conditions
Staphylococcus aureus carriage
Beyond the preview
Go deeper on NCT05889351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05889351.